At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 9 enrolled
Drug / intervention
BI 409306 (C-13/N-15) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Absolute Bioavailability and Pharmacokinetics of BI 409306 Using a Single Oral Dose of BI 409306 Co-administered With an Intravenous Stable Labeled Isotope BI 409306 (C-13/N-15) in Healthy Male and Female Subjects (Non-Randomised, Open-label, Single Arm, Single Period Design)
In Brief
A Phase 1 clinical trial evaluating BI 409306 (C-13/N-15) and BI 409306 for Healthy. Completed, enrolled 9 participants across 1 site.
Detailed Summary
The primary objective of this trial is to investigate the absolute bioavailability of BI 409306. The secondary objective is the evaluation and comparison of several pharmacokinetic parameters for the different treatments.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartApr 2018
Primary CompletionMay 2018
TodayJul 2026
First PostedApr 23, 2018
Enrollment StartApr 27, 2018
Primary CompletionMay 19, 2018
TodayJul 2, 2026
Enrollment to primary: 22 daysPosted 8.2 years ago
Interventions
BI 409306 (C-13/N-15)drug
i.v solution
BI 409306drug
Film-coated tablet